Navigation Links
ERT to Present at Lazard Capital Markets' 7th Annual Healthcare Conference on November 16, 2010
Date:11/12/2010

PHILADELPHIA, Nov. 12, 2010 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), announced today that Dr. Michael J. McKelvey, the Company's President and CEO, is scheduled to present at Lazard Capital Markets' 7th Annual Healthcare Conference at 10:55 AM EST on November 16, 2010 in New York City, New York.

Interested parties may access the presentation by visiting the Company's corporate website at http://www.ert.com. The webcast may also be accessed at http://www.wsw.com/webcast/lz8/eres/.  The webcast will be available via replay for 90 days.

About ERT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries.  The Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. It is also a leading provider of centralized respiratory technology and services to evaluate pulmonary function efficacy and safety in clinical development.  Sponsors can further use the Company's solutions to streamline the clinical trials process by automating the collection, analysis, and distribution of ePRO clinical data using multi-mode technology in all phases of clinical development as well as selected medical devices for the clinical trials and healthcare industries.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties, which could cause actual results to differ materially from those expressed or implied from such statements. These risks and uncertainties include, without limitation, the Company's ability to obtain new contracts, variability in size, scope, and duration of projects, integration of acquisitions, competitive factors, technological development, market demand, and other factors described in the Company's filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE ERT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InfraReDx Announces Presentation of LipiScan™ Research at American Heart Association Scientific Sessions 2010
2. Philips and American Heart Association Present Fourth Annual Resuscitation Fellowship Award
3. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
4. Jazz Pharmaceuticals Announces Presentation at the Lazard Capital Markets Healthcare Conference on November 17
5. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
6. NexBio Presents Data at ACAAI 2010 Demonstrating Mechanism of Action for Improvement in Airway Function by DAS181 (Fludase®*)
7. Kendle to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
9. Thoratec Announces Webcast of Investor Presentation at American Heart Association Meeting
10. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
11. Access Pharmaceuticals Presents CobOral™ Insulin Research at 10th Annual Diabetes Technology Meeting on November 11-13, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 As a result ... with the prevalence of allergic diseases, cutting edge ... currently revolutionising the ways in which pharmaceutical and ... 2017 promises to be both a high quality ... allergy interest groups, immunologists, research scholars and doctors. ...
(Date:3/23/2017)... Summary Global ... guide Primary Hyperoxaluria - Pipeline Review, H1 2017, ... Urinary System And Sex Hormones) pipeline landscape. ... recurrent kidney and bladder stones. It results from ... include blood in the urine, pain when urinating, ...
(Date:3/23/2017)... and VANCOUVER, British Columbia , ... SPHS ) (the "Company" or "Sophiris"), a clinical ... of urological diseases, today announced that data from its ... drug as a focal treatment for localized prostate cancer, ... 2017 at the 32 nd Annual European Association ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is ... in Building 2. The clinic is the group’s second in New Braunfels and 22nd ... company’s second New Braunfels location brings things full circle for the group, “It’s crazy ...
(Date:3/23/2017)... ... ... 82% of adults are unaware of the dangers that infectious bacteria play in mouth disease, ... times a day that dentists recommend. The ramifications of improper oral upkeep go far beyond ... missing 164 million hours of work each year due to dental issues. That is why ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... Oriented Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s asthma, coronary ... , Accredited status is granted to organizations that have excellent programs for the ...
(Date:3/23/2017)... Fort Collins, CO (PRWEB) , ... March 23, ... ... services firm serving the families and businesses of the greater Fort Collins area, ... charity campaign in their ongoing community involvement program. Donations to this worthy cause ...
(Date:3/23/2017)... ... ... conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... 43rd President of the United States of America: George W. Bush , ... the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh ...
Breaking Medicine News(10 mins):